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Abstract
Purpose The purpose of this study was to compare longitudi-
nal data on drug utilization between 10-year-old children and
15-year-old adolescents and to analyse the association of drug
use at the age of 15 years with drug use at the age of 10 years.
Methods Based on the German GINIplus (German infant
study on the Influence of Nutrition Intervention plus
environmental and genetic influences on allergy develop-
ment) and LISAplus (Influence of lifestyle factors on the
immune system and allergies in East and West Germany
plus the influence of traffic emissions and genetics) birth
cohorts, data on drug utilization (past 4 weeks) were
collected using a self-administered questionnaire for
3642 children (10-year follow-up) and 4677 adolescents
(15-year follow-up). The drugs were classified by
therapeutic categories (conventional drugs, homeopathic
drugs, etc.) and by codes according to the anatomical
therapeutic chemical (ATC) classification system. Asso-
ciations of adolescents’ drug use with gender, study
area, maternal education, parental income, presence
of chronic conditions, and prior drug use at the age
of 10 years were analysed using a logistic regression
model.
Results The 4-week prevalence rates of overall drug use
were similar for adolescents (41.1 %) and children
(42.3 %). However, adolescents used noticeably more
anti-inflammatory drugs, analgesics, and systemic anti-
histamines. Exactly 3194 children/adolescents partici-
pated in both follow-ups. Adolescents’ use of anti-
inflammatory drugs was predicted (OR=3.37) by use
of anti-inflammatory drugs as a child. In summary,
the strongest predictor of adolescents’ use of specific
therapeutic categories or ATC groups was the previous
use of the same therapeutic drug category or ATC
group as a 10-year-old child.
Conclusions Despite similar prevalence rates of overall
drug utilization among both age groups, there is a no-
ticeable difference concerning the use of drugs from
specific ATC groups. Drug use as a child may partly
determine what they use as an adolescent.
Keywords Adolescent . Child . Drug utilization .
Longitudinal study . Anti-inflammatory drugs . Germany
Electronic supplementary material The online version of this article
(doi:10.1007/s00228-015-1977-x) contains supplementary material,
which is available to authorized users.
* Salvatore Italia
salvatore.italia@maastrichtuniversity.nl
1 Department of International Health, School for Public Health and
Primary Care (CAPHRI), Faculty of Health, Medicine and Life
Sciences, Maastricht University, Duboisdomein 30, 6229
GT Maastricht, The Netherlands
2 Helmholtz Zentrum München, German Research Center for
Environmental Health, Institute of Epidemiology I,
Neuherberg, Germany
3 Research Institute, Department of Pediatrics, Marien-Hospital Wesel,
Pastor-Janßen-Str. 8-38, 46483 Wesel, Germany
4 Department of Environmental Immunology, UFZ – Helmholtz
Centre for Environmental Research Leipzig, Permoserstr. 15,
04318 Leipzig, Germany
5 Helmholtz Zentrum München, German Research Center for
Environmental Health, Institute of Health Economics and Health
Care Management, Ingolstädter Landstraße 1,
85764 Neuherberg, Germany
Eur J Clin Pharmacol (2016) 72:301–310
DOI 10.1007/s00228-015-1977-x
Introduction
Pharmaceutical products play an important role in the
health system, both from the medical point of view as
well as in economic terms. In Germany, the turnover in
medicinal products (prescription drugs and self-
medicated drugs together) amounted to about 34 billion
euros in 2013 [1]. At about 30 billion euros, expendi-
tures on medicinal products accounted for about 16 %
of the total expenditures covered by the German statu-
tory health insurance companies. They ranked third
among their expenditure items in 2013 [1], only
exceeded by costs of hospital treatments (65 billion
euros) and medical expenses (32 billion euros). Accord-
ing to available publications, the prevalence of drug use
is generally quite high among adolescents in Germany
and other European countries as well. In Germany, a 1-
week prevalence for overall drug use (prescription drugs
and self-medicated drugs together) of 50.7 % was re-
ported for adolescents aged 14–17 years [2]. Another
German study that included both prescription drugs
and self-medicated drugs found that 41 % of 15-year-
old adolescents used at least one drug within an obser-
vation period of 4 weeks [3]. A Spanish study yielded
similar results, with 31.6 % of children older than
10 years using prescription drugs or over-the-counter
(OTC) drugs during the last 2 weeks prior to the as-
sessment [4]. In other studies from Denmark, Italy, and
the Netherlands that analysed prescription drug use only,
the 1-year prevalence ranged between 38 and 57 %
[5–9]. Moreover, the share of self-medicated drugs
among all drugs used by adolescents may be consider-
able (e.g. reported at 69 % among 15-year-old adoles-
cents and 38.5 % among children aged 0–17 years, re-
spectively, from two German studies [2, 10]). Further
European studies yielded prevalence rates for OTC drug or
self-medicated drug use during childhood or adolescence of
17–39 % (use within the last 2 days) in Finland [11, 12], about
35% (2-week prevalence) in the Netherlands [13], and 67% (1-
year prevalence) in Sweden [14]. The evidently high prevalence
of (self-medicated) drug use among the general adolescent pop-
ulation raises some public health questions, e.g. whether all of
the drugs taken are medically advisable and appropriate, or
whether some self-medicated drugs such as analgesics are con-
sidered by adolescents to be ordinary commodities that may
become part of everyday life over time.
The aim of this study is to analyse drug utilization longitu-
dinally among children from two German birth cohorts by
comparing drug use at two defined time points (at the age of
10 and 15 years, respectively). A further objective of this
study was to detect whether there was an association of drug




The GINIplus study (German infant study on the Influ-
ence of Nutrition Intervention plus environmental and
genetic influences on allergy development) and the
LISAplus study (Influence of lifestyle factors on the
immune system and allergies in East and West Germany
plus the influence of traffic emissions and genetics) are
based on two German birth cohorts [15, 16] that started
with 5991 (GINIplus) and 3097 (LISAplus) healthy full-
term newborns who were recruited between September
1995 and January 1999 from obstetric clinics in four
German regions (Munich, Leipzig, Bad Honnef, Wesel).
The recruitments sites were chosen to achieve an almost
heterogeneous sample with regard to geographic region
(South Germany: Munich; East Germany: Leipzig; West
Germany: Bad Honnef and Wesel) and degree of urban-
ization (urban areas: Munich and Leipzig; comparatively
rural areas: Bad Honnef and Wesel). From both studies,
non-term children and children of less than 2500 g birth
weight were excluded. Children with non-German par-
ents or parents born outside Germany were not enrolled
for the LISAplus study. Additionally, participants with
insufficient German language skills were not eligible for
both cohorts.
Data collection
For the 15-year follow-up, exactly 6094 participants’ par-
ents or legal guardians were contacted between January
2011 and October 2014. Socioeconomic variables such as
parental education and income were collected with the
main questionnaire, which also assessed the participants’
gender. Additionally, a separate self-administered question-
naire on drug utilization within the past 4 weeks assessed
various details on the drugs that had been used by the
adolescents within the past 4 weeks. The participants were
asked to enter the drug names and the pharmaceutical
identification numbers (PZN) into five designated spaces
or to enclose the empty drug packages in a self-addressed
envelope. The PZN, which is printed on the drug package,
exactly identifies the drugs with respect to package size,
dosage, manufacturer, listed price, etc. In case the limited
number of designated spaces was not sufficient to enter all
drugs, the participants were invited to separately note the
precise number of drugs used. An almost similar method-
ology was adopted for the 10-year follow-up, in which
6541 parents/legal guardians had been contacted between
October 2006 and October 2009. Exactly 3194 subjects
participated in the 10-year follow-up and the 15-year fol-
low-up as well.
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Drug classification
According to the German Medicines Act, homeopathic,
anthroposophic, and herbal products are defined as medicinal
products as well. Therefore, all reported drugs were consid-
ered for analysis and were classified into several therapeutic
modalities such as conventional drugs with chemical active
pharmaceutical ingredients, homeopathic drugs, and herbal
drugs. The exact definition of the various therapeutic modal-
ities has been described in detail in a previously published
study [17]. If available, codes were assigned to the drugs ac-
cording to the anatomical therapeutic chemical (ATC) classi-
fication system [18, 19].
Outcome definition and statistical analysis
Participants who reported use of at least one drug from any
therapeutic category within the past 4 weeks were classified as
‘overall drug users’. Those participants taking one or more
drugs from a specific drug category (e.g. homeopathic drugs)
or ATC group (e.g. ATC N02 for ‘analgesics’) were classified
as users of the respective drug category (e.g. ‘homeopathy
users’) or ATC group (e.g. ‘analgesic users’).
For analysis, the statistical software package SASwas used
(SAS Institute Inc., Cary, NC, USA, version 9.3). Bivariate
associations were tested with the Pearson chi2 test (p<0.05).
Interaction between the independent variables was checked
using Pearson’s correlation coefficients. Odds ratios (ORs)
and their 95 % confidence intervals (CIs) were obtained from
a multivariate logistic regression model that included several
independent variables (study area, child’s gender, maternal
education, parental income, presence of a child’s chronic dis-
ease, previous use of the same defined drug categories or ATC
groups at the age of 10 years). In addition, for all models, a
stepwise backward elimination procedure was performed at a
significance level for removal from the model with p≥0.05.
Associations with p<0.05 were considered to be significant.
Mothers rather than fathers may decide on the (self-) medica-
tion of their children. Thus, for the definition of educational
status, the mothers’ educational background was used. To ac-
count for differences in school systems betweenWest and East
Germany before reunification in 1990, maternal education
was classified into three levels based on the mothers’ maxi-
mum completed years of schooling:
Level 1: low education level (<10 years)
Level 2: medium education level (exactly 10 years)
Level 3: high education level (>10 years)
Mothers who did not report any school degree at all (n=26)
were allocated to the low education level. Entries for mothers
(n=14) reporting another (but not further specified) kind of
school degree than those listed above were treated as missing
values for educational status.
Income status was classified following the median equiva-
lent income (MEI) of 2012 (€1,633 net/month for the 15-year
follow-up) and 2008 (€1,549 net/month for the 10-year fol-
low-up) [20, 21], where the household members were weight-
ed according to the new scale of the Organisation for Econom-
ic Co-operation and Development (OECD) [22]. Three in-
come levels were defined: low (≤60 % of MEI), medium
(60–100 % of MEI), and high (>100 % of MEI). The income
cutoffs correspond to the definition of poverty (60 % of MEI)
[23].
To take into account also the impact of chronic disorders on
drug use, adolescents were defined as chronically ill if the
participants reported the diagnosis of a chronic disease by a
physician during the preceding 5 years. The following chronic
conditions (physician diagnosed) were considered: hay fever,
perennial allergic rhinitis, food allergy, atopic dermatitis, and
asthma. Additionally, also further self-reported chronic condi-
tions such as diabetes, and celiac disease were considered.
The GINIplus and LISAplus cohorts obtained approval
from the ethics committees of the Bavarian Medical Council,
the University of Leipzig, and the Medical Council of North
Rhine-Westphalia. Furthermore, written informed consent
was given by the participants’ parents or legal guardians and
by participants.
Results
The questionnaires on drug utilization were completed for
3642 children at the 10-year follow-up (response rate
55.7 %) and 4677 adolescents at the 15-year follow-up (re-
sponse rate 76.8 %). Compared with baseline, both samples
showed no variation with regard to gender (p=0.9936 (10-
year follow-up); p=0.4437 (15-year follow-up)), while the
composition differed significantly with regard to study area
(p<0.0001 (10-year follow-up); p=0.0023 (15-year follow-
up)) and maternal education (both samples at p<0.0001).
The differences between the samples in the 10-year follow-
up and the 15-year follow-up were not significant with regard
to gender (p=0.5375) and maternal education (p=0.3696),
whereas both samples varied significantly (p<0.0001) with
regard to study area and household income. The detailed com-
position of the cohorts over time is displayed in Table 1. The
total number of reported drugs amounted to 3215 drugs in the
10-year follow-up and 3873 drugs in the 15-year follow-up.
In summary, there was no statistically significant difference
(p=0.2555) with regard to the prevalence rates of overall drug
use between 15-year-old adolescents (41.1 %; 95 % CI 39.7–
42.5) and 10-year-old children (42.3 %; 95 % CI 40.7–43.9).
About 71% of the drugs used by adolescents were OTC drugs
(29 % were prescription drugs). The corresponding figures for
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10-year-old children were 75 % (OTC drugs) and 25 % (pre-
scription drugs). Compared with 10-year-old children, 15-
year-old adolescents used fewer homeopathic and herbal
drugs, whereas they took more conventional drugs containing
chemical active ingredients (Supplementary Figure S1). The
respective prevalence rates of use differed significantly be-
tween both age groups at p<0.0001 (homeopathy use),
p<0.0001 (use of herbal drugs), and p=0.0006 (use of con-
ventional drugs). Overall, adolescents took fewer OTC drugs
than children (p=0.0077).
The 12 most frequent ATC codes in each follow-up, which
accounted for 36.3 % (10-year follow-up) and 37.6 % (10-
year follow-up) of all reported drugs in the corresponding
follow-up, are displayed in Table 2. In the 10-year follow-
up, one single homeopathic remedy (Arnica globules (n=
59), not listed in Table 2 as no ATC code available), was also
among the most mentioned drugs. Four out of 12 of the most
commonly used active ingredients that were taken by adoles-
cents were anti-inflammatory agents (ibuprofen, naproxen) or
analgesics (paracetamol, acetylsalicylic acid).
The comparison by ATC group (Fig. 1) revealed that ado-
lescents took fewer drugs from the ATC groups R03 (drugs for
obstructive airway diseases; p<0.0001), R05 (cough and cold
preparations; p<0.0001), and R01 (nasal preparations; p=
0.0076). On the other hand, they used substantially more
(p<0.0001) anti-inflammatory drugs (ATC M01) and some-
what more analgesics (ATC N02; p=0.0323), antihistamines
(ATC R06; p<0.0006), and drugs for functional gastrointesti-
nal disorders (ATC A03; p<0.0001).
A detailed view of the prevalence rates of anti-
inflammatory drug use and analgesic use, which increased
from 4.6 % (95 % CI 3.9–5.3) to 11.2 % (95 % CI 10.3–
12.1) and from 6.0 % (95 % CI 5.2–6.7) to 6.6 % (95 % CI
5.9–7.3), respectively, showed that the higher prevalence rates
among adolescents resulted mainly from an increase in the
female stratum (Fig. 2), where 15-year-old girls used, for ex-
ample, more than three times the number of anti-inflammatory
drugs (4.9 % (95 % CI 3.8–5.9) vs. 14.8 % (95 % CI 13.3–
16.2)). Additionally, there was no gender difference with re-
gard to the use of anti-inflammatory drugs or analgesics
among 10-year-old children, whereas 15-year-old girls used
significantly more anti-inflammatory drugs or analgesics than
15-year-old boys (Fig. 2).
Medication tracking
From the 3642 children who participated in the 10-year fol-
low-up, exactly 3194 (87.7 %) were still in the GINIplus/
LISAplus cohorts at the 15-year follow-up. Adolescents were
more than twice as likely (OR=2.25; 95 % CI 1.94–2.61) to
Table 1 Characteristics of the
GINIplus and LISAplus cohort
over time
Distribution of the strata in % p valueb
Baseline 10-year follow-up 15-year follow-up
Total number of participants 9088 3642 4677
Gender
Male 51.3 51.3 50.6 0.5375
Female 48.7 48.7 49.4
Study area
Munich 48.6 50.8 50.1 <0.0001
Leipzig 10.7 10.5 8.9
Bad Honnef 3.4 5.4 4.0
Wesel 37.3 33.3 37.0
Maternal education
Low 16.0 9.8 10.7 0.3696
Medium 39.0 39.4 38.6
High 45.0 50.8 50.7
Household incomea
≤60 % of MEI 16.8 17.0 <0.0001
60–100 % of MEI NA 44.2 37.9
>100 % of MEI 39.0 45.1
MEI median equivalent income (MEI not available for the baseline survey), NA not available
a Based on the MEI of 2008 (€1,549; 10-year follow-up) and on the MEI of 2012 (€1,633; 15-year follow-up)
b Derived from chi2 test, testing the difference of the sample composition between the 15-year follow-up and the
10-year follow-up
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be an ‘overall drug user’ if they had already been an ‘overall
drug user’ at the age of 10 years. With regard to the use of the
various drug categories (Table 3), the likelihood of being a
drug user of the same drug category at the age of 10 years
and as an adolescent as well was highest for homeopathic
drugs (OR=3.82; 95 % CI 2.91–5.00).
The independent variables for previous use of conventional
drugs, homeopathy, and herbal drugs, as displayed in Table 3,
remained in the models after performing a backward
elimination procedure. The longitudinal association of drug
use was also given for various ATC groups. Table 4 shows
the odds ratios of drug utilization from the most commonATC
groups (except ATC group G03, where no use was reported
among 10-year-old children), derived from the final multivar-
iate logistic regression model with backward elimination.
In most instances, the strongest predictor of adolescents’
drug use was the previous use of drugs from the same ATC
group at the age of 10 years. For example, adolescents used
Table 2 Most frequent ATC codes (absolute number and percentage of all reported drugs)
10-year follow-up 15-year follow-up
ATC Active ingredient n % ATC Active ingredient n %
N02BE01 Paracetamol 191 5.9 M01AE01 Ibuprofen 484 12.5
M01AE01 Ibuprofen 169 5.3 N02BE01 Paracetamol 204 5.3
R01AA07 Xylometazoline 125 3.9 N06BA04 Methylphenidate 108 2.8
R03AC02 Salbutamol 114 3.5 R06AE07 Cetirizine 101 2.6
N06BA04 Methylphenidate 99 3.1 R01AA07 Xylometazoline 101 2.6
R05CB01 Acetylcysteine 91 2.8 R03AC02 Salbutamol 85 2.2
R05CB06 Ambroxol 76 2.4 R05CB01 Acetylcysteine 82 2.1
R01BP30 Systemic rhinologicalsa 68 2.1 R01BP30 Systemic rhinologicalsa 74 1.9
R05CP02 Ivy leaves 68 2.1 R05XH20 Homeopathic flu remediesa 59 1.5
R05XH20 Homeopathic flu remediesa 62 1.9 H03CA01 Iodide 56 1.4
R03BA02 Budesonide 54 1.7 N02BA01 Acetylsalicylic acid 54 1.4
R06AE07 Cetirizine 53 1.6 M01AE02 Naproxen 50 1.3
3215 drugs used at the 10-year follow-up and 3873 at the 15-year follow-up
ATC anatomical therapeutic chemical classification system
aCombined preparations
Fig. 1 Comparison by ATC
codes (only ATC groups with n>
15 in the 15-year follow-up
considered, reflecting 79 % of all
drugs used at the age of 15 years
and 70 % of all drugs used at the
age of 10 years). The displayed
proportions refer to all reported
drugs of the respective follow-up
(n=3215 drugs at 10-year follow-
up and n=3873 drugs at the 15-
year follow-up)
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Fig. 2 Prevalence of use of anti-
inflammatory drugs and
analgesics stratified by gender
Table 3 Predictors of use of conventional drugs, homeopathic drugs, and herbal drugs (full models without backward elimination)
Adjusted odds ratio of utilization (and 95 % confidence interval)
Conventional drugs Homeopathic drugs Herbal drugs
Gender
Male Reference Reference Reference
Female 1.54** (1.32–1.79) 1.57* (1.22–2.02) 1.33 (1.00–1.78)
Study area
Munich Reference Reference Reference
Leipzig 0.91 (0.70–1.19) 1.10 (0.72–1.69) 1.50 (0.94–2.39)
Bad Honnef 1.25 (0.88–1.78) 1.11 (0.62–1.97) 1.48 (0.80–2.76)
Wesel 1.07 (0.89–1.28) 0.86 (0.64–1.17) 1.30 (0.92–1.83)
Maternal education
Low Reference Reference Reference
Medium 1.42 (1.05–1.92) 1.92 (1.05–3.51) 1.77 (0.87–3.60)
High 1.43 (1.05–1.93) 2.10 (1.15–3.83) 2.33 (1.15–4.74)
Household income
Low Reference Reference Reference
Medium 1.22 (0.95–1.57) 1.09 (0.70–1.69) 1.32 (0.82–2.12)
High 1.08 (0.83–1.40) 1.05 (0.67–1.64) 0.90 (0.55–1.49)
Chronic diseasea
No Reference Reference Reference
Yes 1.98** (1.68–2.34) 1.53 (1.18–1.99) 1.20 (0.87–1.64)
Previous use of conventional drugsb
No Reference
Yes 2.45** (2.08–2.88)
Previous use of homeopathic drugsb
No Reference
Yes 3.82** (2.91–5.00)
Previous use of herbal drugsb
No Reference
Yes 3.28** (2.29–4.71)
Italicized numbers are significant at p<0.05
*p<0.01; **p<0.0001
aDiagnosed by a physician during the preceding 5 years
b Use at the age of 10 years
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significantly more antibacterials (OR=3.95; 95 % CI 1.75–
8.91), anti-inflammatory drugs (OR=3.37; 95 % CI 2.28–
4.99), analgesics (OR=3.25; 95 % CI 2.13–4.94), or throat
preparations (OR=3.74; 95 % CI 1.67–8.38), if they had used
drugs from the same ATC group 5 years before. The
continuity of using the same type of drugs was visible for
some very narrowly defined ATC subgroups as well, e.g. the
use of ibuprofen (ATC M01AE01), paracetamol (ATC
N02BE01), or mucolytics (R05CB) as an adolescent was pre-
dicted by the prior use of ibuprofen (OR=3.71; 95% CI 2.49–
Table 4 Odds ratios of drug use for various ATC groups (multivariate logistic regression model with backward elimination)
ATC groups
A03 H03 J01 M01 N02 N06 R01 R02 R03 R05 R06
Gender (Ref=male) 8.56** b b 2.09** 1.71* b b b b b b
Study area (Ref=Munich) b b b b b b b b b b b
Leipzig b b b 0.71a b b b b b b b
Bad Honnef b b b 1.64 b b b b b b b
Wesel b b b 0.77a b b b b b b b
Maternal education (Ref=low) b b b b b b b b b b b
Medium b b b b b b b b b b b
High b b b b b b b b b b b
Parental income (Ref=low) b b b b b b b b b b b
Medium b 0.32* b 0.97a b 0.56a b b b b 1.23a
High b 0.29* b 1.32a b 0.28* b b b b 1.87a
Chronic disease (Ref=no) b b b b b b 1.91** b 8.71** b 7.36**
Previous use of A03 (Ref=no) b b b b b b b b b b b
Previous use of H03 (Ref=no) b 78.97** b b b b b b b b b
Previous use of J01 (Ref=no) b b 3.95* b b b b b 3.82* b b
Previous use of M01 (Ref=no) b b b 3.37** b b 2.11* b b b b
Previous use of N02 (Ref=no) 2.50 b b 2.84** 3.25** b b b b b b
Previous use of N06 (Ref=no) b b b b b 89.28** b b b b b
Previous use of R01 (Ref=no) b b b b b b 2.54** b b b b
Previous use of R02 (Ref=no) b b 2.83 b 2.37* b b 3.74* b b b
Previous use of R03 (Ref=no) b b b 1.93* b b b b 17.71** b 2.65*
Previous use of R05 (Ref=no) b b b 1.38 b b b b b 2.21** 1.91
Previous use of R06 (Ref=no) b b b b b b 2.26* b b b 5.38**




J01, antibacterials for systemic use
R03, drugs for obstructive airway diseases
M01, anti-inflammatory drugs
R05, cough and cold preparations
N02, analgesics
R06, antihistamines for systemic use
N06, psychoanaleptics
Ref reference
Point estimates in italics were significant at p<0.05
*significant at p<0.01
**significant at p<0.0001
aVariable remained in the final model, but the calculated point estimate was not significant at p<0.05
bVariable removed from the model by backward elimination
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5.53), paracetamol (OR=3.80; 95 % CI: 2.29–6.30), or mu-
colytics (OR=3.67; 95 % CI: 1.88–7.16), respectively, at the
age of 10 years. The model fit statistics for all regression
models shown in Tables 3 and 4 were satisfactory (p at least
p<0.05). A detailed table that also contains the 95 % CI of the
ORs shown in Table 4 is available as supplementary material
to this article (Supplementary Table S2).
Discussion
The findings of this study revealed that the prevalence of
overall drug use was almost at the same level when comparing
15-year-old adolescents with 10-year-old children. At the
same time, there was a noticeable difference in drug utilization
with regard to specific ATC groups, e.g. a significantly higher
use of anti-inflammatory drugs (ATC M01) among 15-year-
old adolescents. The gender difference among 15-year-old
adolescents may presumably in part result from the fact that
female adolescents use e.g. ibuprofen for period pains. A high
paediatric use of anti-inflammatory drugs or analgesics was
also found in other European studies [2, 10, 14, 24–26]. Gen-
erally, the high prevalence of drug use raises the question of
whether all the drugs used by adolescents were really medi-
cally necessary or advisable, not least in view of the fact that
medicinal products such as anti-inflammatory drugs, analge-
sics, or antihistamines can also have severe side effects
[27–29].
Another finding of this study was that adolescents used
fewer homeopathic drugs and herbal drugs. Other studies
analysing herbal drug use only [30] or various complementary
and alternative medicine (CAM) modalities [31] also found
lower prevalence rates for herbal drugs or homeopathy. This
may be explained in part by the fact that OTC drugs (almost
all homeopathic and herbal drugs were OTC drugs) are not
normally reimbursed by German statutory insurance compa-
nies for children older than 12 years [32], but a lower accep-
tance of homeopathy or phytotherapy might also be a reason
for the lower prevalence rates found for adolescents, as ado-
lescents may begin to take their own decisions on self-
medication with drugs. Moreover, the perception that homeo-
pathic or herbal drugs are supposedly gentle remedies (one
possible reason for their high use among children) may de-
crease or may play a less important role during transition to
adolescence. A further striking outcome was that adolescents’
drug use from a specific ATC group was strongly predicted by
the previous use of a drug from the same ATC group. This
could have been expected for drugs that are used for the treat-
ment of chronic or persistent conditions such as asthma, atten-
tion deficit and hyperactivity disorder, or thyroid disorders.
On the other hand, this is a remarkable result for medicinal
products (prescribed drugs as well as self-medicated drugs)
that are supposedly used predominantly to treat an acute
condition such as antibiotics, anti-inflammatory drugs, or an-
algesics. With regard to analgesics, another study [33] yielded
a similar result, finding a strong association between headache
medicine use at the age of 27 years and prior use of headache
medicine at the age of 15 or 19 years.
An additional aspect that has to be considered is the
difference between both age groups with regard to the
proportion of prescribed drugs. While most (64 %) of
the drugs used by 10-year-old children were prescribed
by a physician (only 36 % were purchased on the partic-
ipants’ own initiative), the share of prescribed drugs may
be much lower among adolescents (this proportion was
not directly assessed in the 15-year follow-up, but may
be estimated at somewhat higher than 30 %, as exactly
29 % were prescription drugs and presumably only a few
of the reported OTC drugs used by adolescents may have
been prescribed or recommended by a physician [32]).
This high share of OTC drugs emphasizes the importance
of personal health literacy and the role of advice from a
physician or a pharmacist with regard to adolescents’ self-
medication with drugs.
This study has strengths and limitations as well. The data
are based on the recently completed follow-ups of two large
German birth cohorts. The data collection for the 15-year fol-
low-up was performed almost evenly over the four seasons,
with slight peaks in April and June, whereas data for the 10-
year follow-up were collected mainly in the autumn (54 %).
Nevertheless, the prevalence rate for overall drug use in the
autumn was roughly at the same level as for all four seasons
together (it was highest in spring and winter and lowest in
summer). The difference between the distributions of data
assessment over the year may also partly explain the different
prevalence rates of use of seasonally sensitive ATC groups
(e.g. cough and cold remedies, anti-allergy). Additionally,
the different composition of both cohorts with regard to study
area and household income may also have contributed to the
different prevalence rates of drug use between both age
groups. Moreover, other socioeconomic variables may also
predict paediatric drug use, but could not be analysed in this
study because of lacking availability (e.g. migration back-
ground). To our knowledge, the number of studies that
analysed longitudinal data on paediatric drug use is very lim-
ited. Owing to the relatively short observation period of
4 weeks, the recall bias may have been minimized. On the
other hand, underreporting may be likely for some types of
drugs (e.g. contraceptives). Furthermore, categorization by the
main ATC groups is relatively rough, as some ATC groups
such as R05 include various types of chemical active ingredi-
ents. On the other hand, similar associations with prior drug
use were found for very narrowly defined ATC groups as well.
Defined daily doses could provide further important data for
the comparison of drug use between both age groups, but were
not considered in this study because for many of the reported
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drugs (e.g. homeopathic drugs or drug entries with an unclear
package size), no defined daily doses were available.
In sum, both studies cannot be considered as being repre-
sentative for the total German population due to arbitrarily
selection of the four study areas, the exclusion criteria at base-
line, and the selective follow-up. Therefore, the results can be
projected to the general German adolescent population to a
limited extent only, as the present cohort may not exactly
reflect the German mean, e.g. with regard to maternal educa-
tion level, parental income, or the adolescents’ general health
status.
Conclusions
Apparently, adolescents’ drug utilization depends partly on
their drug use as children and may also determine what they
will use in adulthood. It should be kept in mind that drugs are
special products and not simple commodities. They should be
utilized according to the need and not following habitual pat-
terns only. In Europe, OTC drugs are also gradually becoming
available outside pharmacies [34, 35] and are often subject to
free advertising. It remains a difficult balancing act between
free availability of medicinal products, adequate drug prices,
and the appropriate use of self-medicated drugs. Overall, a
good advice on the safe use of self-medication drugs might
best be ensured by pharmacies [36, 37] rather than non-
medical sale points such as supermarkets or petrol stations.
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